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the b&2-adrenoceptor gene have been shown to have functional consequences as a 
result of receptor desensitization associated with certain genetic variants. Accordingly, 
we hypothesized that the common Argl6IGln27 b&2-adrenoceptor polymorphism 
would affect pulmonary function in CHF. METHODS. 54 consecutive, stable CHF 
patients ware genotyped at codon 16 and 27 of the b&2-adrenoceptor gene. Pulmonary 
function tests were performed at rest in patients with the two most common combined 
homozygous polymorphisms: ArglGArglGln27Gln (n=6) and Glyl6GlylGlu27Glu (n=l6). 
RESULTS. Left ventricular ejection fraction, cardiac index, diastolic and systolic diame- 
ters were similar in the two groups. However, patients in the ArglGArg/Gln27Gln group 
were found to have significantly lower percent predicted vital capacity (76+6 vs. 94+4, 
p=O.O4), diflusion capacity (82*7 vs. 95&, ~~0.047) and alveolar volume (84*6 vs. 
99*4, p=O.O35), in the presence of normal flow rates. CONCLUSIONS. Argl6 and Gln27 
homozygosity of the b&2-adrenoceptor gene is associated with restrictive pulmonary 
function at rest in patients with stable, treated CHF. Although the exact mechanisms of 
this phenomenon are unknown, it may be related to the differential effects of beta2- 
adrenoceptor polymorphisms on bet&adrenoceptor-mediated transalveolar fluid clear- 
ance. 
1206-76 Correlates of Quality of Life in Advanced Heart Failure: 
Insights From the Acorn Trial 
Paul J. Hauptman, D. Wentworth. Spencer Kubo, on behalf of the Acorn Investigators. 
Saint Louis University, St. Louis, MO, Acorn Cardiovascular, St. Paul, MN 
Background: Quality of life (QoL) measurement in heart failure (HF) is an important end- 
point in randomized device trials. Patient characteristics may differ from drug studies 
(e.g. younger age) due to higher perceived risks of surgery. The Acorn CorCap, a surgi- 
cally implanted cardiac support device intended to reduce wall stress and induce reverse 
remodeling, is under evaluation in NYHA II- early IV HF. Two strata - severe mitral ragur- 
gitation (MR) that requires valve repair/replacement (MVR) and cardiomyopathy without 
need for concomitant surgery - also permits assessment of the effect of MR on QoL. 
Methods: Baseline QoL (MLHFQ; SF-36). B-minute walk distance (GMWD), end-diastolic 
dimension, ejection fraction, peak V02 and comorbidities (diabetes, etc) were collected 
(N=lOB). Correlation coefficients and multivariable predictors of QoL scores were deter- 
mined. Results: The score on MLHFQ correlated inversely with 8MWD (-0.33, p<O.OOl), 
age (-0.30, p.zO.05) and SF-36 physical functioning (-0.64) and general health (-0.55) 
domains (both pcO.0001). Age and 6MWD were predictors of MLHFQ score (table). Con- 
trolling for EDDINYHA, MR severity or need for MVR did not impact QoL. Each IOOm 
increase in 6MWD and 10-y increase in age were associated with 9.5 and 7.4 point 
improvements in MLHFQ score respectively. Conclusions: In the CorCap support device 
trial, age and 8MWD but not MR severity predict QoL on MLHFQ. Follow-up data will 
assess whether these factors remain predictive over time and after intervention. 
Predictors of MLHFQ ~mre by quartile 
~48 (best) 48-62 63.78 79+ (worst) Adjusted pvalue 
6MWD (m) 394 342 360 308 0.0002 
LVEDD (mm) 68.1 72.7 68.0 70.7 0.46 
LVEF (%) 23.0 22.4 22.9 22.4 0.34 
Ags (Y) 57.9 53.0 51.8 47.1 <0.0001 
Peak V02 15.8 13.3 16.1 14.5 0.77 
MR grade 2.6 2.2 2.2 2.5 0.28 
Time since HF diagnosis 6.1 5.1 5.2 34 0.11 
(Y) 
Comorbidities(mean #) 1.3 1.8 1.9 1.2 0.05 
1206-77 Heart Block After Alcohol Septal Ablation: Predictors 
and Consequences 
Annabel A. Cherr Danita M. Yoerger, Michael H. Picard, lgor F. Palacios, Gus J. 
Vlahakes, Michael A. Fifer, Massachusetts General Hospital, Harvard Medical School, 
Boston, MA 
Background: Conduction defects after alcohol septal ablation for hypertrophic obstruc- 
tive cardiomyopathy are common, with complete heart block (CHB) requiring permanent 
pacemaker (PPM) occurring in up to 33% of patients (pts). 
Methods: 37 consecutive pts (23 female. age 58+1-16 yrs) underwent 39 ablation proce- 
dures between September 1998 and August 2002. Five pts with prior PPM and 1 pt who 
did not receive alcohol due to unfavorable septal anatomy were excluded from analysis. 
Resu11s: In the remaining 33 procedures, CHB occurred during ablation in 20 (61%). 
After ablation, 8 pts had new RBBB, 2 RBBB+LAFB, 3 RBBB+LPFB, and 2 LBBB. Nine 
pts (27%) developed CHB 32+/-15 hours after ablation. 3 of whom had asystole with no 
ventricular escape rhythm. Eight received PPM and 1, moribund on an LVAD before 
ablation, died after subsequent surgical myectomy. PPM was also placed in 1 pt with 
prior intermittent RBBB+LAFB who developed LBBB after ablation. All pts who received 
PPM had CHB during ablation and/or a new intraventricular conduction defect (IVCD) 
afterwards. PPM was ultimately required in 8 of 20 pts with CHB during ablation corn- 
pared to 1 of 12 pts without (p=O.O4). of the 9 pts who received PPM, 7 had a new IVCD 
after ablation; the other 2 had preexisting IVCD. The 2 pts who underwent repeat abla- 
tion both received PPM. Between pts who did and did not receive PPM, there was no sig- 
nificant difference in volume of alcohol used (2.4 vs 3.0 ml), acute reduction in left 
ventricular outflow tract (LVOT) gradient (45 vs 57 mmHg), or peak CK (1550 YS 1403 U). 
Three-month follow-up available for 28 pts showed no significant difference in NYHA 
class improvement (2.9 to 1.9 YS 2.9 to 1.7) or proportion with 50% LVOT gradient reduc- 
tion (75% vs 55%). 
Conclusions: 1) Pts without CHB during ablation or new IVCD after ablation are at low 
risk for later CHB requiring PPM. 2) The risk of CHB requiring PPM may be especially 
high with repeat ablation. 3) Occurrence of CHB requiring PPM does not correlate with 
infarct size or acute or 3.month ablation succsss. 4) Some pts with CHB have no escape 
rhythm; in pts with CHB during ablation or new IVCD afterwards, temporary pacing 
should be provided for at least 48 hours after ablation. 
1206-78 Right Ventricular Recovery Post-Lung Transplantation 
in Patients With Pretransplant Pulmonary Hypertension 
on Contemporary Medical Therapy 
Javier Jimenez, Debra Fertel, Ruben Servian, Sandra Gerity, Joseph Bauerlein, Martin 
Bilsker, Howard Willens, Si Pham, Stephen Mallon, Jackson Memorial Medical Center, 
Miami, FL 
Background: Improved medical management of patients with non-cardiac pulmonary 
hypertension has lead to improved survival; however, development of long-standing 
sswxe right ventricular dysfuncion is more commonly seen. 
Objectives: To evaluate echocardiographic paramenters of right ventricular recovery 
after lung transplantation in pre-transplant pulmonary hypertension patients on contem- 
porary medical therapy. 
Methods: We evaluated patients undergoing lung transplantation at our institution. Diag- 
nosis pre-transplant included idiopathic pulmonary fibrosis, COPD, primary pulmonary 
hypeltension and others. Patients with evidence of pulmonary hypertension on echocar- 
diography or right heart catheterization were selected. Echocardiographic paramenters 
were evaluated pra and post lung transplantation to determine evidence of right ventricu- 
lar reco”ery. 
Results: Thirty patients underwent lung transplantation between 1996 and 2001; of those 
16 (53%) had evidence of pulmonary hypertension. The mean age was 43 SD1 1 years 
and 50% ware of female gender. Echocardiographic paramenters pre and post lung 
transplantation are shown below. 
Conclusions: Severe pulmonary hypertension with right ventricular dysfunction remains 
common in patients referred for lung transplantation. Negative right ventricular remodel- 
ing with normalization of right ventricular echocardiographic paramentes still occurs 
despite prolongued survival on contemporary medical therapy. 
Variable Pre-lung TX Post-lung TX p Value 
RV wall thickness (mm) 7.75 SE 0.73 6.12 SE 0.74 0.04 
RV wall diameter (mm) 35.5 SE 3.34 22.54 SE 1.73 0.01 
RA diameter (mm) 41 SE 4.91 34.3 SE 0.6 0.23 
RV systolic pressure (mm Hg) 77.22 SE 14 36 SE 3.58 0.02 
LV ejection fraction (%) 58 SE 3.1 62 SE 1.3 0.22 
TR Grade 2.56 SE 0.5 1.55 SE 0.34 0.07 
1206-79 Methamphetamine Abuse Is Associated With Left 
Ventricular Dysfunction 
Nader M. Banki Neil Siecke, Thomas Waltman. Ori Ben-Yehuda, University of California, I- 
San Diego, San Diego, CA 
Background: 8.8 million Americans including 4.4% of high school students have tried 
methamphetamine (m&h) at least once in their lifetimes. Anecdotal reports of cardiomyo- 
pathies in meth abusers have been reported. We sought to determine the incidence of 
left ventricular (LV) dysfunction in patients with documented meth use. 
Methods: We pertormed a query of the toxicology database of the UCSD Medical Center 
for all patients with positive screens for meth from November 1999 to June 2002. We 
identified all patients who also had a transthoracic echocardiogram (TrE) wtthin one year 
of testing positive. Age matched non-amphetamine positive patients were used as con- 
trols. 
Findings: A total of 843 toxicology screens tested positive for meth. Of these, 76 had a 
TTE and comprise the study population. The average age was 43 j: 9. 49i76 (64%) 
patients had normal LV function, 8f78 (8%) mild, 8/76 (11%) moderate, and 13i76 (17%) 
severe LV dysfunction. The corresponding numbers for 1295 age-matched patients was 
85% normal, 8% mild, 4% moderate and 4% severe LV dysfunction (p<O.OOl vs. meth 
users). On multi-variate analysis, concomitant HIV disease as well as the presence of 
additional illicit drugs or alcohol were not predictive of LV dysfunction. Conclusion: In 
this group of methamphetamine users we identified a significantly increased incidence of 
LV dysfunction, with 28% having moderate to severe dysfunction. Further COmmUnity- 
based studies of the cardiac effects of methamphetamine abuse appear warranted. 
Left Ventricular Function in Methamphetamine Abusers and Controls 
Mean Age N Normal Mild Moderate Severe 
Math Positive 43+/-g 76 49 (64%) 6 (8%) 8(11%) 13(17%) 
Math Only 44+/-8 18 10(56%) 0 3(17%) 5(26%) 
Meth 8 Cocaine 48+/-t 1 13 10(77%) 0 3(23%) 0 
controts 44+/-4 1295 1097(85%) 100(6%) 46(4%) 52(4%) 
